Automating Dermatology Naviguard Prior Authorizations

Navigating prior authorizations for dermatology practices, especially with complex utilization management programs like Naviguard, demands precision and efficiency. Klivira automates the submission and tracking of dermatology Naviguard PAs, integrating directly with your EMR to reduce administrative burden.

Dermatology prior authorizations often involve high-cost biologics, specialized procedures like Mohs surgery, and intricate step-therapy protocols. When these workflows intersect with Naviguard's utilization management requirements, the administrative overhead can significantly impact revenue cycles and patient access. Klivira provides a robust solution designed to manage these complexities.

The Challenge of Dermatology Naviguard Prior Authorizations

Dermatology practices face unique challenges in securing prior authorizations, particularly for high-value treatments and procedures. Naviguard, as a utilization management program under UnitedHealthcare (UHG), introduces specific clinical criteria and submission pathways that require meticulous documentation and timely follow-up. This intersection often leads to delays, denials, and increased staff workload without an automated solution.

Key PA Triggers in Dermatology Subject to Naviguard Review

Naviguard's utilization management criteria frequently apply to high-cost dermatological treatments. These include biologics for chronic conditions like psoriasis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi) and atopic dermatitis (e.g., Dupixent, Adbry), as well as specialty topicals and advanced skin cancer treatments. Mohs micrographic surgery, especially for non-melanoma skin cancers in cosmetically sensitive areas, is also a common target for payer policy review.

Critical Documentation for Naviguard Dermatology PAs

Diagnosis and severity scores (e.g., PASI/BSA for psoriasis, EASI/SCORAD for atopic dermatitis).
Documentation of prior topical, phototherapy, or conventional systemic therapy trials (e.g., methotrexate, cyclosporine).
Pre-biologic screenings for tuberculosis and hepatitis, where applicable.
Adherence to AAD Clinical Guidelines and NCCN guidelines for skin cancers.
Mohs Appropriate Use Criteria (AUC) conformance for site and tumor type.

Klivira's Automated Approach to Dermatology Naviguard PAs

Klivira streamlines the prior authorization process for dermatology practices interacting with Naviguard by automating data extraction from EMRs and intelligent submission. Our platform applies AAD-guideline-aware step-therapy logic for biologics and validates Mohs surgery against AUC, ensuring submissions meet payer-specific requirements from the outset. This reduces manual effort and accelerates approval times.

EMR and Payer Touchpoints for Efficient Dermatology PA

Klivira integrates seamlessly with major EMR systems using SMART on FHIR standards, extracting necessary clinical data for dermatology PAs, including medication orders, procedure codes, and diagnostic results. For Naviguard submissions, our platform connects to relevant payer portals and leverages electronic prior authorization (ePA) channels, including X12 278 and NCPDP SCRIPT, to ensure efficient and compliant communication with UnitedHealthcare's utilization management programs.

Addressing Common Naviguard Denial Reasons in Dermatology

Common denial reasons for dermatology PAs under Naviguard often involve incomplete step-therapy documentation for biologics, lack of biosimilar substitution justification, or discrepancies with Mohs AUC. Klivira's system proactively identifies and flags these potential issues before submission, guiding staff to provide the necessary information, such as detailed documentation of prior conventional therapy or appropriate severity scores, to mitigate denials.

Frequently asked questions

How does Klivira handle periodic re-authorization for chronic dermatology conditions?

Klivira's platform includes a dedicated workflow for managing periodic re-authorizations common in chronic biologic treatments for conditions like psoriasis or atopic dermatitis. It tracks approval expiry dates and proactively initiates the re-authorization process, ensuring continuous patient access to critical medications without interruption.

Can Klivira differentiate between medical and pharmacy benefit for dermatology biologics?

Yes, Klivira's system is designed to distinguish between medical and pharmacy benefit routing for dermatology biologics, particularly for self-injected at-home medications versus clinic-administered infusions. This ensures the correct prior authorization pathway is followed, reducing submission errors and delays.

How does Klivira support Mohs surgery prior authorizations with Naviguard?

Klivira incorporates logic to validate Mohs surgery prior authorizations against AAD Appropriate Use Criteria (AUC), which is often referenced by utilization management programs like Naviguard. The platform prompts for required documentation such as site, tumor type, and prior treatments, helping ensure submissions align with payer policies.

Does Klivira integrate with my EMR to pull dermatology-specific clinical data?

Yes, Klivira integrates with leading EMR systems via SMART on FHIR to automatically extract dermatology-specific clinical data. This includes diagnosis codes, procedure orders, medication histories, and severity scores (e.g., PASI, EASI, BSA) necessary for comprehensive Naviguard prior authorization submissions.

How does Klivira help address step therapy requirements for dermatology biologics?

Klivira's platform is configured with AAD-guideline-aware step-therapy logic for dermatology biologics. It guides users to document trials of prior topical, phototherapy, or conventional systemic therapies (e.g., methotrexate, cyclosporine), ensuring that Naviguard's step-therapy requirements are met and clearly articulated in the PA submission.